Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.globenewswire.com/news-release/2023/02/21/2611806/37146/en/Amydis-Announces-Enrollment-of-Cerebral-Amyloid-Angiopathy-Participants-in-Phase-1-2a-Retinal-Tracer-Trial.html
0
0
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial - GlobeNewswire
+ 43 more
2/21/23 at 2:00am
Organization
GlobeNewswire
Authors
Amydis
Inc.
Details
39 words
Summarize
Health
Neurological Conditions
Aging & Geriatrics
Amydis Inc.
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants
Retinal Tracer Trial
GLOBE NEWSWIRE
San Diego
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable......
Show more
1 similar article
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial - BioSpace
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...